Coxiella burnetii (Q-Fever) Antibody IgG, Phase I and II with Reflex to Titer
Ordering Recommendation
Confirm infectious agent as C. burnetii (Q-fever) in symptomatic patients. Recommend testing of acute and convalescent sera.
New York DOH Approval Status
Specimen Required
Serum separator tube (SST).
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.4 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as "acute" and "convalescent."
Refrigerated.
Contaminated, hemolyzed, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Methodology
Semi-Quantitative Indirect Fluorescent Antibody (IFA)
Performed
Mon, Wed, Fri
Reported
1-6 days
Reference Interval
Test Number | Component | Reference Interval |
---|---|---|
C. burnetii (Q-Fever) Ab, Phase I IgG | Negative | |
C. burnetii (Q-Fever) Ab, Phase II IgG | Negative |
Interpretive Data
Single phase II IgG titers of 1:256 and greater are considered evidence of C. burnetii infection at some time prior to the date of the serum specimen. Phase I antibody titers of 1:16 and greater are consistent with chronic infection or convalescent phase of Q-fever.
FDA
Note
If either C. Burnetii Abs IgG Phase I and/or Phase II result is indeterminate or positive, then titer(s) will be added. Additional charges apply.
Hotline History
Hotline History
CPT Codes
86638 x2; if reflexed add 86638 per titer
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2012626 | C. Burnetii Abs, IgG Phase I Screen | 48720-7 |
2012628 | C. Burnetii Abs, IgG Phase II Screen | 48719-9 |
Aliases
- Coxiella burnetii
- Coxiella Titer
- Q Fever Phases I and II antibody